Company news
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) news
Eloxx Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 11, 2026: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study…
Press releases & updates
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 11, 2026
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity
May 5, 2026
ELOX: Sixth Amendment adds bridge and Tranche 2 loans, PIK interest, and new agent SD MF 4 LLC
March 17, 2026
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 19, 2023
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
August 14, 2023
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
August 3, 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 12, 2023
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
July 10, 2023